Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Bladder cancer in 2012

Challenging current paradigms

Nature Reviews Urology volume 10, pages 67–68 (2013)Cite this article

Subjects

2012 has been a promising year for patients with bladder cancer. Published reports have challenged current knowledge in areas ranging from disease aetiology to second-line chemotherapy. However, advances in the care of this cancer lag behind those in many other malignancies, reflecting the low priority of bladder cancer to many research funders.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Fernández, M. I., López, J. F., Vivaldi, B. & Coz, F. Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure. J. Urol. 187, 856–861 (2012).

    Article  PubMed  Google Scholar 

  2. Mamtani, R. et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J. Natl Cancer Inst. 104, 1411–1421 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Di Stasi, S. M. et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 12, 871–879 (2011).

    Article  CAS  PubMed  Google Scholar 

  4. Colombo, R. et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur. Urol. 62, 797–802 (2012).

    Article  CAS  PubMed  Google Scholar 

  5. van Rhijn, B. W. et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur. Urol. 61, 378–384 (2012).

    Article  PubMed  Google Scholar 

  6. Lammers, R. J., Witjes, W. P., Janzing-Pastors, M. H., Caris, C. T. & Witjes, J. A. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J. Clin. Oncol. 30, 2273–2279 (2012).

    Article  CAS  PubMed  Google Scholar 

  7. James, N. D. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N. Engl. J. Med. 366, 1477–1488 (2012).

    Article  CAS  PubMed  Google Scholar 

  8. Bellmunt, J. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J. Clin. Oncol. 30, 1107–1113 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Necchi, A. et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 13, 810–816 (2012).

    Article  CAS  PubMed  Google Scholar 

  10. Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Cancer Studies and Academic Urology Unit, G Floor, The Medical School, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK

    Aidan P. Noon & James W. F. Catto

Authors
  1. Aidan P. Noon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James W. F. Catto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James W. F. Catto.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Noon, A., Catto, J. Challenging current paradigms. Nat Rev Urol 10, 67–68 (2013). https://doi.org/10.1038/nrurol.2012.252

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2012.252

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing